Dr. Maya Berdzenishvili, MD

Dr. Berdzenishvili practices at Life Care Center of Stoneham in Stoneham, Massachusetts.

Dr. Berdzenishvili's NPI, 1568557098, was assigned on October 3, 2006. Dr. Berdzenishvili holds Massachusetts license 216073.

Dr. Berdzenishvili's primary practice is Life Care Center of Stoneham, at 25 Woodland Road, Stoneham, MA 02180 in Middlesex County. The practice phone is (781) 662-2545.

Dr. Berdzenishvili's primary practice is Life Care Center of Stoneham in Stoneham, Massachusetts. Dr. Berdzenishvili is also affiliated with South Shore Hospital. The medical group on file is Coastal Medical Associates. Dmand AI also links Dr. Berdzenishvili to 2 more hospitals, 4 hospices, 3 skilled nursing facilities, 3 medical groups, 1 group practice or clinic and 1 senior living community, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Berdzenishvili practices, 13 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Berdzenishvili's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Berdzenishvili is licensed in Massachusetts.

CMS data shows 1,562 Medicare services from Dr. Berdzenishvili across 9 procedure codes in 2024, for 711 Medicare patients. Medicare paid $165,226 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 711 Medicare patients who saw Dr. Berdzenishvili in 2024. The largest group is 85 and over, with 276 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 50% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Berdzenishvili's median patient age at 81, with 59% women.

In 2024, Dr. Berdzenishvili wrote 16,279 Medicare Part D claims for 513 patients. 82% of them were for generic drugs. CMS names the drug for 15,470 of them, across 212 drugs with 11 or more claims each, at $920,383 in total drug cost. In 2023, CMS named 14,124 claims across 199 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 23 out of 100 for Dr. Berdzenishvili for performance year 2024, reported individually. Dr. Berdzenishvili accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Dr. Berdzenishvili from 1 drug or device company in 2018. Food and beverage make up the largest share, 100% of the total. GlaxoSmithKline, LLC. paid the most, $111.